China-based biopharmas reported higher Q1 revenues and profits last week: American Oriental Bioengineering, Mindray Medical, and Simcere Pharmaceutical all started off the year with new levels of performance. The SFDA will introduce rules to shorten the wait for IND rulings for innovative drugs, Venturepharm Asia, revealed plans to build two labs in Jiangsu province, WuXi PharmaTech postponed a secondary stock offering, GlaxoSmithKline created a new division to focus on emerging markets, BMP Sunstone received clearance to begin human trials of Enablex®, and Takara Bio Inc. began testing a cancer immunotherapy in China. More details... Stock Symbols: ( NYSE: AOB ) ( NYSE: MR ) ( NSDQ: DSCP ) ( NYSE: SCR ) ( NYSE: WX ) ( NYSE: GSK ) ( NSDQ: BJGP ) ( NYSE: NVS ) (TSE: 4974)